Modeling the cost-effectiveness of health programs: HIV testing and early treatment in the USA.


Beck, EJ; (2011) Modeling the cost-effectiveness of health programs: HIV testing and early treatment in the USA. Future Microbiol, 6. pp. 725-9. ISSN 1746-0913 DOI: https://doi.org/10.2217/fmb.11.63

Full text not available from this repository.

Abstract

Evaluation of: Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann. Intern. Med. 153(12), 778-789 (2010). The recent results from the NIH HIV Prevention Trials Network (HPTN) 052 trial, confirmed the relationship between plasma viral load and degree of infectivity of people living with HIV (PLHIV); when PLHIV are treated with antiretroviral therapy (ART), their infectivity is significantly reduced. This reiterates the importance of 'treatment for prevention', as well as the therapeutic function of ART. This and other studies raise a number of important questions, including when to start ART. Given the substantial number of PLHIV that are unaware that they are infected, should policy-makers set-up specific programs to identify these PLHIV and get them into treatment early? Long et al. tried to answer this question by modeling the cost-effectiveness of an expanded screening and treatment program in the USA but how good was their model, how can modeling exercises assist policy-makers in answering these difficult questions and what are some of the broader implications?

Item Type: Article
PubMed ID: 21797687
Web of Science ID: 293798700006
URI: http://researchonline.lshtm.ac.uk/id/eprint/20183

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
257Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item